# Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS

> **NCT05153525** · PHASE4 · UNKNOWN · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Respiratory Distress Syndrome, Pediatric
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

## Interventions

- **DRUG:** Intermittent boluses of Cisatracurium
- **DRUG:** Intravenous infusion of Cisatracurium for 24 hours

## Key facts

- **NCT ID:** NCT05153525
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-06
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-08-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153525, "Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05153525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*